<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606163</url>
  </required_header>
  <id_info>
    <org_study_id>GC1102</org_study_id>
    <nct_id>NCT01606163</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of healthy male&#xD;
      adults when subjects are repeatedly administered GC1102 (Hepabig_Gene) through intravenous&#xD;
      injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of GC1102 when repeatedly administered by intravenous injection to healthy male adults</measure>
    <time_frame>screening, -1d, 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 9d, 14d, 21d, 28d</time_frame>
    <description>Adverse event&#xD;
Diagnostic examinations&#xD;
Physical examinations&#xD;
Vital signs&#xD;
ECG(electrocardiogram)&#xD;
Check of concomitant drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GC1102 when repeatedly administered by intravenous injection to healthy male adults</measure>
    <time_frame>1)1d:predose(0h), 0.5, 1, 2, 5, 9, 14 hours after dose 2) 2d~6d:predose(0h) 3) 7d:predose(0h), 0.5, 1, 2, 5, 9, 14 hours after dose 4) 8d, 9d, 14d, 21d, 28d: 0h</time_frame>
    <description>Terminal elimination half-life (t½β)&#xD;
Maximum and Average concentration at steady state(Cmax,ss, Cav,ss,)&#xD;
Area-under the concentration-time curve within a dosing interval at steady state (AUCτ,ss)&#xD;
Clearance (CL)&#xD;
Volume of distribution at steady state (Vd,ss)&#xD;
Mean residence time (MRT)&#xD;
Accumulation Index (AI)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:GC1102&#xD;
Amount:3ml (30,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: GC1102&#xD;
Amount: 5ml(50,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: GC1102&#xD;
Amount: 8ml (80,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug: JW normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1102</intervention_name>
    <description>Description: GC1102 IV bolus injection during 10~ 30 seconds.&#xD;
Amount: group1-3ml, group2-5ml, group3-8ml&#xD;
Subject number: group1-8, group2-8, group3-8&#xD;
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <other_name>Hepabig_Gene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JW normal saline</intervention_name>
    <description>Description: Normal saline IV bolus injection through 10~ 30 seconds.&#xD;
Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.&#xD;
Subject number: 9&#xD;
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)</description>
    <arm_group_label>group 4</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those who are healthy, male adult aged 20 years- 45 years when screened.&#xD;
&#xD;
          -  Those whose body weights are over 45kg when screened, and whose BMI scores are&#xD;
             19kg/㎡-28 kg/㎡.&#xD;
&#xD;
          -  Those whose HBs-Ag, HBc-Ab(IgM), HBc-Ab(IgG), HBV DNA quantitative are all negative&#xD;
             when screened.&#xD;
&#xD;
          -  Those whose HBs-Ab(titer) in blood is below 500 IU/L when screened.&#xD;
&#xD;
          -  Those who agree to use double protective contraceptive measures from one days before&#xD;
             administration of first investigative drug to last follow-up visit(protective&#xD;
             contraceptive measures using more than 2 ways among a male condom, a female condom of&#xD;
             sex partner, a spermicide of sex partner, an intrauterine device(IUD) of sex partner,&#xD;
             a diaphragm of sex partner and a cervical cap of sex partner), and not to provide&#xD;
             sperm.&#xD;
&#xD;
          -  Those who voluntarily decide to follow matters that require attention of this study&#xD;
             and give written consent to participate in this clinical trial.&#xD;
&#xD;
          -  Those who can visit the medical center to be monitored, and agree to collect blood&#xD;
             during study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have GC1102 anti-body when screened&#xD;
&#xD;
          -  Those who have a clinically meaningful disease or history concerning liver, kidney,&#xD;
             alimentary system, respiratory system, musculoskeletal system, endocrine system,&#xD;
             neuropsychiatry system, blood tumor system, cardiovascular system.&#xD;
&#xD;
          -  Those who have anaphylaxis of drug allergy including HBIG or who have allergy disease&#xD;
             requiring treatment.&#xD;
&#xD;
          -  Those who have immunodeficiency disease now.&#xD;
&#xD;
          -  Those who have an anamnesis of Guillain-Barre syndrome.&#xD;
&#xD;
          -  Hemophiliac patients who have a risk of serious bleeding when getting a shot through&#xD;
             intravascular injection or those who are being administered anticoagulants&#xD;
&#xD;
          -  Those who are administered live vaccine parenterally within 120 days from being&#xD;
             administered first investigative drug. (ex: measles vaccine, epidemic parotitis&#xD;
             vaccine, rubella vaccine, cholera vaccine, chickenpox vaccine)&#xD;
&#xD;
          -  Those who are administered interferon or antiviral agents within 120 days from being&#xD;
             administered first investigative drug. (except for topical medication)&#xD;
&#xD;
          -  Those who showed signs of an acute fever(over 38℃) within 72 hours from being&#xD;
             administered first investigative drug.&#xD;
&#xD;
          -  Those who showed signs of acute disease within 14 days from being administered first&#xD;
             investigative drug.&#xD;
&#xD;
          -  Those who donated whole blood within 60 days or ingredient blood within 30 days from&#xD;
             being administered first investigative drug or those who are administered blood&#xD;
             transfusion within 30 days from being administered first investigative drug.&#xD;
&#xD;
          -  Those who took other investigative drugs within 60 days from being administered first&#xD;
             investigative drug.&#xD;
&#xD;
          -  Those who took herbal medicine within 30 days from being administered first&#xD;
             investigative drug or took ethical drug(ETC) within 14 days or took over-the- counter&#xD;
             drug(OTC) within 7 days from being administered first investigative drug.(but, Those&#xD;
             who meet other conditions can join the clinical trials according to investigator's&#xD;
             decision)&#xD;
&#xD;
          -  Those who drink excessively caffeine-contained beverage, excessive alcohol, and who&#xD;
             are smokers( caffeine&gt; 5 units/ day, alcohol&gt;21 units/ week, cigarette&gt; 10 pieces) or&#xD;
             have a history of alcoholism&#xD;
&#xD;
          -  Those who have a history of drug addiction, or showed positive response of urine-drug&#xD;
             screening examination (ex: amphetamine, methamphetamine, barbiturate, cocaine, opiate,&#xD;
             benzodiazepines, cannabinoid, methadone, etc)&#xD;
&#xD;
          -  Those who showed positive sign of serum test(A-type hepatitis test(HAV IgM Ab), C-type&#xD;
             hepatitis test(HCV Ab screening), HIV test(HIV Ag &amp; Ab), Syphilis high quality reagin&#xD;
             test.&#xD;
&#xD;
          -  Those whose serum creatinine, ALT, AST, or total bilirubin exceeded the standard 1.5&#xD;
             times by the diagnostic lab test.&#xD;
&#xD;
          -  Those who cannot eat standard meals provided by Seoul Asan medical center.&#xD;
&#xD;
          -  Those who are judged disqualified to join clinical trials by investigator for other&#xD;
             causes.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of clinical pharmacology and therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of clinical pharmacology and therapeutics</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>January 1, 2014</last_update_submitted>
  <last_update_submitted_qc>January 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

